JP2016523095A - エマルション安定性の改善された組成物及び栄養製品 - Google Patents
エマルション安定性の改善された組成物及び栄養製品 Download PDFInfo
- Publication number
- JP2016523095A JP2016523095A JP2016522549A JP2016522549A JP2016523095A JP 2016523095 A JP2016523095 A JP 2016523095A JP 2016522549 A JP2016522549 A JP 2016522549A JP 2016522549 A JP2016522549 A JP 2016522549A JP 2016523095 A JP2016523095 A JP 2016523095A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- phospholipase
- lecithin
- composition
- nutritional product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 128
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 128
- 239000000839 emulsion Substances 0.000 title claims abstract description 40
- 239000000787 lecithin Substances 0.000 claims abstract description 100
- 235000010445 lecithin Nutrition 0.000 claims abstract description 100
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 97
- 229940067606 lecithin Drugs 0.000 claims abstract description 97
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 94
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 87
- 102000015439 Phospholipases Human genes 0.000 claims abstract description 72
- 108010064785 Phospholipases Proteins 0.000 claims abstract description 72
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims abstract description 66
- 235000013336 milk Nutrition 0.000 claims abstract description 63
- 239000008267 milk Substances 0.000 claims abstract description 63
- 210000004080 milk Anatomy 0.000 claims abstract description 63
- 235000018102 proteins Nutrition 0.000 claims description 92
- 235000013350 formula milk Nutrition 0.000 claims description 50
- 108010046377 Whey Proteins Proteins 0.000 claims description 41
- 102000007544 Whey Proteins Human genes 0.000 claims description 40
- 239000003531 protein hydrolysate Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 235000015097 nutrients Nutrition 0.000 claims description 23
- 108010058864 Phospholipases A2 Proteins 0.000 claims description 21
- 235000021119 whey protein Nutrition 0.000 claims description 19
- 230000035764 nutrition Effects 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000003995 emulsifying agent Substances 0.000 claims description 17
- 230000000774 hypoallergenic effect Effects 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 230000007065 protein hydrolysis Effects 0.000 claims description 12
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 11
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 7
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 102100037611 Lysophospholipase Human genes 0.000 claims 1
- 230000009144 enzymatic modification Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 110
- 108090000631 Trypsin Proteins 0.000 description 34
- 102000004142 Trypsin Human genes 0.000 description 34
- 239000012588 trypsin Substances 0.000 description 32
- 239000007788 liquid Substances 0.000 description 31
- 239000003925 fat Substances 0.000 description 27
- 235000019197 fats Nutrition 0.000 description 27
- 102100037883 Phospholipase B1, membrane-associated Human genes 0.000 description 24
- 239000005862 Whey Substances 0.000 description 22
- 238000006460 hydrolysis reaction Methods 0.000 description 22
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 239000003921 oil Substances 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 19
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 18
- 230000007062 hydrolysis Effects 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 230000008569 process Effects 0.000 description 14
- 102000035195 Peptidases Human genes 0.000 description 13
- 108091005804 Peptidases Proteins 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 150000003904 phospholipids Chemical class 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 230000017854 proteolysis Effects 0.000 description 13
- 108010009736 Protein Hydrolysates Proteins 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000002779 inactivation Effects 0.000 description 11
- 239000004365 Protease Substances 0.000 description 10
- 150000004665 fatty acids Chemical class 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 230000001810 trypsinlike Effects 0.000 description 9
- 102000005593 Endopeptidases Human genes 0.000 description 8
- 108010059378 Endopeptidases Proteins 0.000 description 8
- 235000021588 free fatty acids Nutrition 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- -1 sorbitan fatty acid esters Chemical class 0.000 description 8
- 102000011420 Phospholipase D Human genes 0.000 description 7
- 108090000553 Phospholipase D Proteins 0.000 description 7
- 102000014384 Type C Phospholipases Human genes 0.000 description 7
- 108010079194 Type C Phospholipases Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 206010025476 Malabsorption Diseases 0.000 description 6
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 239000008347 soybean phospholipid Substances 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 5
- 108020002496 Lysophospholipase Proteins 0.000 description 5
- 230000001079 digestive effect Effects 0.000 description 5
- 230000035611 feeding Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- 230000002797 proteolythic effect Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 241000223221 Fusarium oxysporum Species 0.000 description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 4
- 241001221335 Nocardiopsis sp. Species 0.000 description 4
- 235000019486 Sunflower oil Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000004667 medium chain fatty acids Chemical class 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002600 sunflower oil Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003637 basic solution Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012084 conversion product Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 229940066758 endopeptidases Drugs 0.000 description 3
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002960 lipid emulsion Substances 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000003623 Hypoalbuminemia Diseases 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 239000008344 egg yolk phospholipid Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 230000006609 metabolic stress Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 125000001095 phosphatidyl group Chemical group 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical class CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241001409157 Anisoplia Species 0.000 description 1
- 241001134258 Brachysporiella Species 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000157311 Kutzneria Species 0.000 description 1
- 241000157308 Kutzneria albida Species 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- VQENOYXMFIFHCY-UHFFFAOYSA-N Monoglyceride citrate Chemical class OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O VQENOYXMFIFHCY-UHFFFAOYSA-N 0.000 description 1
- 241000203622 Nocardiopsis Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 208000035010 Term birth Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- HUTIVPWAVQGKQA-UHFFFAOYSA-N calcium;octadecyl 2-hydroxypropanoate Chemical compound [Ca].CCCCCCCCCCCCCCCCCCOC(=O)C(C)O HUTIVPWAVQGKQA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
- A23J3/08—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L35/00—Food or foodstuffs not provided for in groups A23L5/00 – A23L33/00; Preparation or treatment thereof
- A23L35/10—Emulsified foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Dairy Products (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
Description
a)少なくとも1つのタンパク質、及び乳レシチンを含む原料混合物を供給する工程、
b)少なくとも1つのホスホリパーゼを添加し、乳レシチンの転化を行う工程、
c)前記タンパク質の加水分解を行う工程。
−本発明によるタンパク質加水分解物を含むタンパク質組成物を供給する工程、及び
−1つ又はそれ以上の栄養素を添加する工程。
a)少なくとも1つのタンパク質、及び乳レシチンを含む原料混合物を供給する工程、
b)少なくとも1つのホスホリパーゼを添加し、乳レシチンの転化を行う工程、及び
c)前記タンパク質の加水分解を行う工程。
タンパク質加水分解は、乳レシチンの転化前に、転化と同時に、又は転化後に実施してもよい。一実施形態において、タンパク質加水分解は、少なくとも1種のホスホリパーゼの添加前、添加と同時、又は添加後からなる群から選択される少なくとも1つの段階で実施されてよい。いくつかの実施形態において、1つ以上のタンパク質加水分解の工程が実施される。本発明の方法の好適な一実施形態において、ホスホリパーゼの工程は、タンパク質加水分解の工程と同時に実施される。
レシチンは、リン脂質を総称するのに使用される用語である。レシチン中に存在可能なリン脂質の例としては、ホスファチジルイノシトール(PI)、ホスファチジル−L−セリン(PS)、ホスファチジルエタノールアミン(PE)、ホスファチジルコリン(PC)、及びスフィンゴミエリン(SP)が挙げられる。レシチン及びリン脂質という用語は、ここでは互換的に用いられる。
そのようなWPCの一例としては、Arla Foods社(DK)のLacprodan(登録商標)DI−87がある。同類の製品として、例えば、Armor(F)、Davisco(USA)、DMV(NL)、Glanbia(IR)、Kerry(IR)、Hilmar(USA)、Fonterra(NZ)も利用可能である。典型的なレシチン濃度は、約0.3〜2g/100gであり、タンパク質濃度は、25〜90%である。
驚いたことに、本発明の発明者らは、乳レシチンを含む組成物へのホスホリパーゼの添加が、乳レシチンの転化、及び遊離脂肪酸及び/又はリゾ−リン脂質などの転化生成物の放出を引き起こし、このことがそれらを含む最終的な栄養製品中のエマルションの品質を向上させるように作用することを発見した。
−例えば乳レシチンを含むホエータンパク質濃縮物を供給することにより、タンパク質及び乳レシチンを供給する工程、
−ホスホリパーゼA2などの、少なくとも1つのホスホリパーゼを添加する工程、及び
−前記タンパク質の加水分解、及びホスホリパーゼの同時処理を実施する工程。
このように、いくつかの実施形態において、タンパク質及び乳レシチンは、例えば液体ホエーなどのホエーを供給することにより、供給される。液体ホエーは、例えば、微生物学的な影響を受ける原料である液体ホエーの輸送が可能となる程度に十分近い任意のWPC製造業者によって原則的に提供され得る。代わりに、ホエータンパク質濃縮物又はホエータンパク質分画物などのホエー粉末を使用してもよい。そのような場合、ホエー粉末を水中で溶解させる。例えば、ホエー粉末は、例えば50〜70℃、55〜60℃、約60℃など、40〜80℃の範囲の温度まで加温した水中で、溶解させてもよい。
上述したように、他の態様として、本発明は上述の発明の方法によって得ることが可能なタンパク質加水分解物を含むタンパク質組成物と関連がある。
d)中鎖脂肪酸トリグリセリド油(MCT)、又は高オレイン酸ヒマワリ油などの油及び/又は脂質の1つ又はそれ以上を添加する工程、及び
e)乾燥の工程。
更なる態様として、本発明は、得ることが可能な又は本発明の方法で得られたタンパク質組成物の、栄養製品の調製における使用と関連がある。
更なる態様として、本発明は、栄養製品の調製法、以下の工程を含む前記方法と関連がある。
a)上述のように、本発明によるタンパク質組成物を供給する工程。
b)1つ又はそれ以上の栄養素を添加する工程。
d)中鎖脂肪酸トリグリセリド油(MCT)、又は高オレイン酸ヒマワリ油などの油及び/又は脂質の1つ又はそれ以上を添加する工程、及び
e)乾燥の工程。
他の態様として、本発明は、発明された栄養製品の調製法によって得ることが可能な栄養製品と関連がある。
なお、本発明の一態様の文脈で記載されている実施形態及び特徴は、発明の他の態様にも当てはまることに注意が必要である。
材料
1250 USP U/mgのトリプシン、及び10’000IU/mgのレシターゼを、Novozymes社より入手した。
約30〜35%の乾燥物質で、部分的に脱塩された液体ホエータンパク質濃縮物と定義される液体ホエー、又はホエータンパク質濃縮物粉末は、Foremost Farms,Baraboo,WI,USより入手した。ラクトース一水和物粉末は、Meggle社(Germany)より入手した。
16kgのホエータンパク質濃縮物粉末、及び11kgのラクトース一水和物粉末を、54kgの脱塩水に溶解し、30%w/wのKOHを添加して、pHを7.4とした。
タンパク質含有量は、総窒素濃度に、係数の6.25を掛けて、計算した。この計算により、65gのトリプシンが必要とされた。
タンパク質加水分解物1kg当たり0.8gの最終濃度となるように、トリプシンを添加した。
4つの異なるバリアントが、実施例1に記載の方法を用いて、作成された。
A.比較的低い固有のホスホリパーゼ活性を有するトリプシン製剤を用いて、実施例1に記載される方法で作成される参照用変異型
B.バリアントは、トリプシン1g当たり約3mg又は11ユニットに相当する、トリプシン1g当たり3μgのホスホリパーゼ10L(膵ホスホリパーゼA2 ex Novozymes,10’000IU/ml)を添加して作成され、このバリアントは2回目の加水分解工程に添加された。
C.Aと同様の方法ではあるが、1.2%の高アミラーゼスターチ、及び安定剤として0.03%のカッパ−カラーギナンを添加して、作成されたバリアント。
D.Aと同様の方法ではあるが、比較的高い固有のホスホリパーゼ活性を持つトリプシン製剤を使用して、作成されたバリアント。
一般的に、粒径値が小さくなれば、エマルションの安定性がよくなる。
病気により食物を全く又は十分に食べることのできなかったり、食欲減退、飲み込みの困難、若しくは摂食を妨げるある種の手術を受けた患者のための、経腸の栄養素用又は経管栄養法用の栄養組成物が、本発明の方法に従い、作成された。
消化の簡単な栄養組成物を、本発明の方法に従い、製造した。
タンパク質加水分解を微生物由来のプロテアーゼを用いて実施するということを除いて、栄養組成物を実施例1に記載される方法で生成する。
タンパク質加水分解をフザリウム・オキシスポラム由来、又はクツネリア・アルビダ由来のトリプシン様エンドペプチダーゼの混合物を用いて、ノカルジオプシスsp.由来、又はメタルジウム・アニソプリア由来のキモトリプシン様エンドペプチダーゼと組み合わせて実施するということを除き、栄養組成物を実施例3に記載される方法で生成する。
タンパク質加水分解をフザリウム・オキシスポラム由来、又はクツネリア・アルビダ由来のトリプシン様エンドペプチダーゼの混合物を用いて、ノカルジオプシスsp.由来、又はメタルジウム・アニソプリア由来のキモトリプシン様エンドペプチダーゼと組み合わせて実施するということを除き、栄養組成物を実施例4に記載される方法で生成する。
Claims (15)
- タンパク質加水分解物を含むタンパク質組成物の調製方法であって、
a)少なくとも1つのタンパク質、及び乳レシチンを含む原料混合物を供給する工程、
b)少なくとも1つのホスホリパーゼを添加し、乳レシチンの転化を行う工程、
c)前記タンパク質の加水分解を行う工程、を含む方法。 - タンパク質加水分解が乳レシチンの転化と同時に実施される、請求項1に記載の方法。
- 前記タンパク質が、ホエータンパク質濃縮物又はホエータンパク質分画物である、請求項1又は2に記載の方法。
- 前記乳レシチンが天然乳レシチンである、請求項1〜3のいずれか一項に記載の方法。
- 前記少なくとも1つのホスホリパーゼが、ホスホリパーゼA1、及び/又はホスホリパーゼA2である、請求項1〜4のいずれか一項に記載の方法。
- 更に以下の工程、
d)油の添加工程、
e)乾燥工程、を含む、請求項1〜5のいずれか一項に記載の方法。 - 請求項1〜6のいずれか一項に記載の方法により得ることが可能なタンパク質加水分解物を含むタンパク質組成物。
- 栄養製品の調製方法であって、以下の工程、
a)請求項7に記載のタンパク質組成物を供給する工程、
b)1つ又はそれ以上の栄養素を添加する工程、を含む方法。 - 請求項8に記載の方法により得ることが可能な栄養製品。
- 前記栄養製品中に存在する唯一の乳化剤が、乳レシチンに由来することを特徴とする、請求項9に記載の栄養製品。
- 前記組成物がエマルション、好ましくは水中油型エマルションである、請求項9又は10に記載の栄養製品。
- 前記組成物が経腸組成物、又は経口組成物である、請求項9〜11のいずれか一項に記載の栄養製品。
- 前記組成物が、低刺激性乳児用フォーミュラ、又は低刺激性ヘルスケア用栄養フォーミュラなどの低刺激性栄養製品である、請求項9〜12のいずれか一項に記載の栄養製品。
- レシチン転化度が少なくとも20%である、請求項9〜13のいずれか一項に記載の栄養製品。
- 栄養製品の調製における、請求項7に記載のタンパク質組成物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13174091.2 | 2013-06-27 | ||
EP13174091 | 2013-06-27 | ||
PCT/EP2014/063781 WO2014207247A1 (en) | 2013-06-27 | 2014-06-27 | Compositions and nutritional products with improved emulsion stability |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019137805A Division JP6764010B2 (ja) | 2013-06-27 | 2019-07-26 | エマルション安定性の改善された組成物及び栄養製品 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2016523095A true JP2016523095A (ja) | 2016-08-08 |
Family
ID=48692344
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016522549A Pending JP2016523095A (ja) | 2013-06-27 | 2014-06-27 | エマルション安定性の改善された組成物及び栄養製品 |
JP2019137805A Active JP6764010B2 (ja) | 2013-06-27 | 2019-07-26 | エマルション安定性の改善された組成物及び栄養製品 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019137805A Active JP6764010B2 (ja) | 2013-06-27 | 2019-07-26 | エマルション安定性の改善された組成物及び栄養製品 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20160150805A1 (ja) |
EP (1) | EP3013159B1 (ja) |
JP (2) | JP2016523095A (ja) |
CN (2) | CN105338835A (ja) |
AU (2) | AU2014300996A1 (ja) |
BR (1) | BR112015031424B1 (ja) |
CA (1) | CA2912755C (ja) |
ES (1) | ES2763652T3 (ja) |
HK (1) | HK1224148A1 (ja) |
MX (1) | MX2015017827A (ja) |
PH (1) | PH12015502623B1 (ja) |
RU (1) | RU2016102556A (ja) |
SG (1) | SG11201509446UA (ja) |
WO (1) | WO2014207247A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018010672B1 (pt) * | 2015-12-18 | 2022-05-10 | Société des Produits Nestlé S.A. | Composições líquidas esterilizadas por calor com alto teor de proteína, seu processo contínuo de preparação, uso de proteína hidrolisada, e método para controlar a viscosidade e evitar o gosto amargo das ditas composições |
WO2017154992A1 (ja) * | 2016-03-10 | 2017-09-14 | 味の素株式会社 | 植物蛋白質含有食品の製造方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH022319A (ja) * | 1987-12-23 | 1990-01-08 | Soc Prod Nestle Sa | アレルギー性を減少させた食品の製造方法 |
JP2004505644A (ja) * | 2000-08-11 | 2004-02-26 | ノボザイムス ノース アメリカ,インコーポレイティド | ホエータンパク質エマルジョン |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4051269A (en) * | 1974-08-29 | 1977-09-27 | Mjolkcentralen, Ekonomisk Forening | Low calorie, high protein tablespreads from sweet milk and their production |
CN1099841A (zh) * | 1993-08-28 | 1995-03-08 | 金刚裕 | 摆动转子式内燃机 |
NL9400757A (nl) | 1994-05-06 | 1995-12-01 | Campina Melkunie Bv | Door hydrolysaten gestabiliseerde hitte-stabiele olie-in-water emulsies. |
MY134684A (en) * | 1995-05-15 | 2007-12-31 | Gist Brocades Bv | Application of phospholipases in animal feed |
TR199701705T1 (xx) * | 1995-06-27 | 1998-04-21 | Unilever N.V. | Trigliserid ya�lar�n i�lenmesinde hareketsiz enzim ve kullan�m�. |
JP2000135427A (ja) * | 1998-10-29 | 2000-05-16 | Taiyo Kagaku Co Ltd | 蛋白複合体からなる乳化剤 |
EP1532863B1 (en) * | 1999-03-16 | 2017-10-25 | Novozymes A/S | Process for producing cheese |
US6551636B2 (en) | 1999-07-23 | 2003-04-22 | Novozymes A/S | Modification of foaming properties of proteins |
AU2001254730A1 (en) * | 2000-03-24 | 2001-10-03 | Societe Des Produits Nestle S.A. | Nutritional composition comprising hydrolysed protein |
AU2002336717B2 (en) * | 2001-11-06 | 2008-04-03 | Novozymes North America, Inc. | Modified whey protein compositions having improved foaming properties |
WO2003071875A1 (en) | 2002-02-21 | 2003-09-04 | Land O'lakes, Inc. | Method of preparing a milk polar lipid enriched concentrate and a sphingolipid enriched concentrate |
US20050129738A1 (en) * | 2002-06-16 | 2005-06-16 | Lipogen Ltd. | Infant formula supplemented with phospholipids |
CN101511206B (zh) * | 2006-07-13 | 2013-07-17 | 雀巢产品技术援助有限公司 | 用于液体营养组合物的稳定剂系统 |
EP1900282A1 (en) * | 2006-08-28 | 2008-03-19 | Puratos N.V. | Method of preparing a cake using phospholipase |
AU2010257548A1 (en) * | 2009-06-10 | 2012-01-12 | Novozymes A/S | Phospholipases and methods of using same |
EP2436389A1 (en) * | 2010-10-01 | 2012-04-04 | Nestec S.A. | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
-
2014
- 2014-06-27 JP JP2016522549A patent/JP2016523095A/ja active Pending
- 2014-06-27 BR BR112015031424-4A patent/BR112015031424B1/pt active IP Right Grant
- 2014-06-27 US US14/901,327 patent/US20160150805A1/en not_active Abandoned
- 2014-06-27 CN CN201480035756.8A patent/CN105338835A/zh active Pending
- 2014-06-27 WO PCT/EP2014/063781 patent/WO2014207247A1/en active Application Filing
- 2014-06-27 AU AU2014300996A patent/AU2014300996A1/en not_active Abandoned
- 2014-06-27 CA CA2912755A patent/CA2912755C/en active Active
- 2014-06-27 ES ES14735541T patent/ES2763652T3/es active Active
- 2014-06-27 MX MX2015017827A patent/MX2015017827A/es unknown
- 2014-06-27 EP EP14735541.6A patent/EP3013159B1/en active Active
- 2014-06-27 CN CN202110265276.2A patent/CN113142595A/zh active Pending
- 2014-06-27 RU RU2016102556A patent/RU2016102556A/ru not_active Application Discontinuation
- 2014-06-27 SG SG11201509446UA patent/SG11201509446UA/en unknown
-
2015
- 2015-11-25 PH PH12015502623A patent/PH12015502623B1/en unknown
-
2016
- 2016-11-02 HK HK16112607.2A patent/HK1224148A1/zh unknown
-
2018
- 2018-04-24 AU AU2018202831A patent/AU2018202831B2/en active Active
-
2019
- 2019-07-26 JP JP2019137805A patent/JP6764010B2/ja active Active
-
2020
- 2020-12-28 US US17/134,773 patent/US20210112826A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH022319A (ja) * | 1987-12-23 | 1990-01-08 | Soc Prod Nestle Sa | アレルギー性を減少させた食品の製造方法 |
JP2004505644A (ja) * | 2000-08-11 | 2004-02-26 | ノボザイムス ノース アメリカ,インコーポレイティド | ホエータンパク質エマルジョン |
Non-Patent Citations (1)
Title |
---|
現代チーズ学, JPN6019010377, 10 October 2008 (2008-10-10), pages 63 - 64, ISSN: 0004002789 * |
Also Published As
Publication number | Publication date |
---|---|
AU2014300996A1 (en) | 2015-11-26 |
WO2014207247A1 (en) | 2014-12-31 |
HK1224148A1 (zh) | 2017-08-18 |
JP6764010B2 (ja) | 2020-09-30 |
EP3013159A1 (en) | 2016-05-04 |
PH12015502623A1 (en) | 2016-03-07 |
BR112015031424B1 (pt) | 2021-06-08 |
ES2763652T3 (es) | 2020-05-29 |
CA2912755A1 (en) | 2014-12-31 |
US20210112826A1 (en) | 2021-04-22 |
SG11201509446UA (en) | 2016-01-28 |
PH12015502623B1 (en) | 2016-03-07 |
CN113142595A (zh) | 2021-07-23 |
CA2912755C (en) | 2021-09-07 |
BR112015031424A2 (pt) | 2017-07-25 |
MX2015017827A (es) | 2016-04-15 |
JP2019205457A (ja) | 2019-12-05 |
AU2018202831A1 (en) | 2018-05-10 |
RU2016102556A (ru) | 2017-08-01 |
EP3013159B1 (en) | 2019-11-13 |
CN105338835A (zh) | 2016-02-17 |
AU2018202831B2 (en) | 2020-03-12 |
US20160150805A1 (en) | 2016-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107846960B (zh) | 含稳定脂质的微胶囊及其制备方法 | |
JPWO2013080911A1 (ja) | 腸内菌叢改善用栄養組成物 | |
US5650190A (en) | Heat-stable oil-in-water emulsions stabilized by hydrolyzates | |
McSweeney | Emulsifiers in infant nutritional products | |
JP2022509814A (ja) | リン脂質と脂肪酸塩の分散体を含む調製物 | |
US20210112826A1 (en) | Compositions and nutritional products with improved emulsion stability | |
JP6719574B2 (ja) | 神経変性疾患の、予防または治療のための組成物 | |
CN112205475B (zh) | 一种结构化乳液 | |
TWI364260B (en) | Nutritional formula comprising l-(+) lactic acid, its preparation method, and uses of l-(+) lactic acid therein | |
RU2703177C2 (ru) | Питание для младенцев с гидролизованным белком, ионным кальцием и пальмитиновой кислотой | |
JP6093300B2 (ja) | がんに伴う不可逆性の代謝障害の予防及び/又は改善のための組成物 | |
JP3579617B2 (ja) | 乳化安定性の良好な栄養組成物 | |
CN114680179A (zh) | 高蛋白浓缩乳及制备方法 | |
CN113115821A (zh) | 含多肽的结构化乳液 | |
CN113660867A (zh) | 在胃条件下显示相分离的营养组合物及其制备方法 | |
FR2876875A1 (fr) | Protection d'ingredients alimentaires bioactifs par encapsulation | |
BR112015009002B1 (pt) | Peptídeos amargos encapsulados, seu método de encapsulamento, e composições nutritivas | |
RU2703172C2 (ru) | Питание для младенцев с гидролизованным белком и пальмитиновой кислотой | |
CN112385845A (zh) | 一种富含opo的结构化乳液 | |
TW201822640A (zh) | 包含麥芽三糖之組成物,及使用彼以抑制由脫水方法導致之傷害的方法 | |
CN116349733A (zh) | 高脂质消化率的婴儿配方奶粉及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170614 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180703 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181003 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190326 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20190614 |